Monday, January 17, 2000
Even though many investors have just discovered genomics, companies
working in the field know that the first chapter in its history is coming to
a close, and they must adapt in order to survive. Two opposing answers to how
to do that are provided by Genset S.A. and Incyte Pharmaceuticals Inc. Both
began as service companies engaged in supplying DNA sequence and analysis data
to aid in drug discovery. But Genset plans to move downstream into product development,
while INCY will remain purely a data and services provider.
Yet another model is provided by Qiagen N.V., which has essentially
quietly grazed for technology during the Chapter I period in order to build
a genomics service platform that it believes will have competitive advantage
in the next era.